破百！ASH2026中国之声，向世界递交中国答卷

多发性骨髓瘤与浆细胞疾病

英文标题：Safety and preliminary efficacy of GPRC5D/CD19 dual-targeted CAR-T cell therapy in relapsed or refractory multiple myeloma: A prospective, single-center, phase I/II clinical trial

中文标题：GPRC5D/CD19 CAR-T细胞治疗RRMM的安全性与初步疗效：一项前瞻性、单中心、I/II期临床试验

报告人：Yangmin Zhu

英文标题：Anti-BCMA CAR T-cell therapy followed by autologous stem cell transplantation and a second CAR T infusion in newly diagnosed multiple myeloma with TP53 abnormalities: A phase 2 trial

中文标题：抗BCMA CAR-T细胞治疗序贯自体干细胞移植及二次CAR-T输注用于伴TP53异常的NDMM：一项2期试验

报告人：Yuntong Liu

英文标题：Initial results from the dose-escalation phase of a first-in-human global phase I study of SIM0500, a novel GPRC5D/BCMA/CD3 trispecific T-cell engager, in relapsed/refractory multiple myeloma

中文标题：新型GPRC5D/BCMA/CD3三特异性T细胞衔接器SIM0500治疗RRMM的首次人体全球I期研究剂量递增阶段初步结果

报告人：Yan Xu

英文标题：IBI3003, a novel GPRC5D× BCMA×CD3 Trispecific antibody, in relapsed or refractory multiple myeloma (R/R MM): Updated Results of a phase 1 study

中文标题：新型GPRC5D×BCMA×CD3三特异性抗体IBI3003治疗RRMM：1期研究结果更新

报告人：Jing Li

英文标题：Teclistamab as first-line therapy for mayo stage iiib light-chain amyloidosis: Preliminary Results from a phase II multicenter trial

中文标题：特立妥单抗一线治疗Mayo IIIb期轻链淀粉样变：一项II期多中心试验的初步结果

报告人：Ai Guan

英文标题：Preliminary analysis of a prospective, single-arm, single-center clinical study of aponermin combined with cybord in newly diagnosed systemic light chain amyloidosis

中文标题：Aponermin联合CyBorD方案治疗新诊断系统性轻链淀粉样变的前瞻性、单臂、单中心临床研究初步分析

报告人：Kai Ding

英文标题：Low-dose BCMA/CD 3 bispecific antibody (CM 336) induces rapid and universal deep hematologic responses in newly diagnosed systemic AL amyloidosis: Primary analysis of the prospective phase 2 AL-003 trial

中文标题：低剂量BCMA/CD3双特异性抗体（CM336）在新诊断系统性AL淀粉样变中诱导快速且普遍的深度血液学缓解：前瞻性2期AL-003试验主要分析

报告人：Qi Wang

英文标题：Daratumumab, venetoclax, and dexamethasone (Dara-VenD) as first-line treatment for t(11;14) light-chain (AL) amyloidosis: Preliminary Results of a phase II prospective, single-arm study

中文标题：达雷妥尤单抗、维奈克拉联合地塞米松（Dara-VenD）一线治疗t(11;14)轻链（AL）淀粉样变：一项II期前瞻性、单臂研究的初步结果

报告人：Ai Guan

急性髓系白血病（AML）

英文标题：Venetoclax, homoharringtonine, aclarubicin, and cytarabine (VHAA) versus daunorubicin and cytarabine (DA) as induction therapy for young adults with newly diagnosed acute myeloid leukemia: Results from a Phase III randomized controlled trial

中文标题：维奈克拉、高三尖杉酯碱、阿克拉霉素联合阿糖胞苷（VHAA）对比柔红霉素联合阿糖胞苷（DA）作为年轻成人新诊断AML的诱导治疗：一项III期随机对照试验结果

报告人：Yi Zhang

英文标题：Venetoclax plus azacitidine and cytarabine in younger unfit patients with newly AML: A cohort from a multi-centre, open-label, single-arm, phase 2 trial

中文标题：维奈克拉联合阿扎胞苷及阿糖胞苷治疗较年轻但不适合强化化疗的新诊断AML患者：一项多中心、开放标签、单臂2期试验队列

报告人：Xiao Han

英文标题：Comparing the efficacy and safety of venetoclax plus azacitidine versus daunorubicin plus cytarabine as induction therapy for young adults with newly diagnosed ELN adverse-risk AML: A multicenter, randomized, superiority, phase 2b trial

中文标题：维奈克拉联合阿扎胞苷对比柔红霉素联合阿糖胞苷作为年轻成人新诊断ELN不良预后AML的诱导治疗：一项多中心、随机、优效性2b期试验

报告人：Man Qiao

英文标题：Venetoclax plus three-day multi-frequency decitabine (DEC3-VEN) versus azacitidine plus venetoclax (AZA-VEN) for newly diagnosed AML in older patients: Updated Results of a multicenter randomized trial

中文标题：维奈克拉联合三日高频地西他滨（DEC3-VEN）对比阿扎胞苷联合维奈克拉（AZA-VEN）治疗老年新诊断AML：一项多中心随机试验的更新结果

报告人：ZePing Zhou

英文标题：Efficacy and safety of aclarubicin added to venetoclax plus hypomethylating agents in older or unfit patients with newly diagnosed acute myeloid leukemia: Results from a multicenter, randomized, phase 2b trial

中文标题：在维奈克拉联合去甲基化药物基础上加用阿克拉霉素治疗老年或不适合强化化疗的新诊断AML：一项多中心、随机2b期试验结果

报告人：Wenjie Liu

英文标题：High rates of MRD negativity with risk-stratified sonrotoclax plus chemotherapy in newly diagnosed acute myeloid leukemia: Preliminary results from a phase II study

中文标题：风险分层指导下索托克拉联合化疗在新诊断AML中实现高MRD阴性率：一项II期研究的初步结果

报告人：Yunxiang Zhang

英文标题：Peripheral blood minimal residual disease-guided preemptive therapy for induction remission in newly diagnosed acute myeloid leukemia

中文标题：外周血MRD指导的新诊断AML诱导缓解期抢先治疗

报告人：Yehui Tan

英文标题：Single-cell multi-omics defines treatment-resistant cell states and a clinically informative classification in acute myeloid leukemia

中文标题：单细胞多组学定义AML中的治疗耐药细胞状态及具临床价值的分型

报告人：Yang Song

英文标题：Hematopoietic differentiation arrest states determine the sensitivity of NPM1-mutated acute myeloid leukemia to menin inhibitor

中文标题：造血分化阻滞状态决定NPM1突变AML对menin抑制剂的敏感性

报告人：Heye Yu

英文标题：Comprehensive characterization of a high-risk mast cell-like leukemia subset in t(8;21) AML and development of its IL5RA-targeted CAR-T therapy

中文标题：伴t(8;21) AML中高危肥大细胞样白血病亚群的全面表征及其IL5RA靶向CAR-T疗法的开发

报告人：Yu Liu

英文标题：Genome-scale in vivo CRISPR screenings identify drivers for transformation from preleukemia to leukemia with t(8;21) translocation

中文标题：全基因组体内CRISPR筛选鉴定t(8;21) AML白血病前期转化的驱动因子

报告人：Ziyu Niu

英文标题：Doxycycline targeting PGC-1a reverses bone marrow stromal cell senescence and enhances chemosensitivity in acute myeloid leukemia

中文标题：多西环素靶向PGC-1α逆转骨髓基质细胞衰老并增强AML的化疗敏感性

报告人：Huifang Huang

英文标题：Integrated clinical, immunophenotypic, and molecular predictors of survival in acute myeloid leukemia with t(9;11)(p21.3;q23.3)/KMT2A::MLLT3:a multicenter retrospective cohort study

中文标题：伴t(9;11)(p21.3;q23.3)/KMT2A::MLLT3 AML生存结局的临床、免疫表型及分子预测因素：一项多中心回顾性队列研究

报告人：Fang Cheng

英文标题：OXCT1-mediated ketolytic metabolism driven AML maintenance and venetoclax resistance through epigenetic reprogramming

中文标题：OXCT1介导的酮解代谢通过表观遗传重编程驱动AML维持与维奈克拉耐药

报告人：Huafeng Wang

英文标题：Genome-wide CRISPR screening identifies non-canonical ATM–DOT1L signaling as a driver of adaptive resistance to mutant IDH1/2 inhibitors in acute myeloid leukemia

中文标题：全基因组CRISPR筛选揭示非经典ATM–DOT1L信号通路是AML对突变型IDH1/2抑制剂适应性耐药的驱动因素

报告人：Mengbao Du

英文标题：PARP8 disruption preserves a progenitor-like exhausted CD8+ T-cell state and enhances CD33-directed CAR T-cell activity in pediatric acute myeloid leukemia

中文标题：破坏PARP8可维持祖细胞样耗竭CD8+ T细胞状态并增强CD33靶向CAR-T细胞在儿童AML中的活性

报告人：Yongping Zhang

英文标题：Targeting Bruton's tyrosine kinase to overcome venetoclax resistance in acute myeloid leuekmia, from bench to bedside

中文标题：靶向BTK克服AML维奈克拉耐药：从基础到临床

报告人：Guo-Pan Yu

MDS与 MPN

英文标题：Safety, tolerability, and efficacy of mesutoclax (ICP-248) combined with azacitidine in patients with treatment-Naïve Myelodysplastic Syndromes (MDS)

中文标题：Mesutoclax（ICP-248）联合阿扎胞苷治疗初治骨髓增生异常肿瘤征（MDS）患者的安全性、耐受性与疗效

报告人：Huafeng Wang

英文标题：An international, randomized, double-blind, placebo-controlled, multicenter Phase 2 study of AK117 plus azacitidine versus placebo plus azacitidine in patients with newly diagnosed (ND) higher-risk myelodysplastic syndromes/neoplasms (HR-MDS): Preliminary results of AK117-205

中文标题：AK117联合阿扎胞苷对比安慰剂联合阿扎胞苷治疗新诊断HR-MDS的国际多中心、随机、双盲、安慰剂对照2期研究：AK117-205初步结果

报告人：Hongyan Tong

英文标题：The IGF2BP3-CBFA2T3 axis links oncogenic KRAS to oxidative phosphorylation in JMML hematopoietic stem and progenitor cells

中文标题：IGF2BP3–CBFA2T3轴连接致癌KRAS与JMML造血干/祖细胞氧化磷酸化

报告人：Jingliao Zhang

CML

英文标题：Association between TKI discontinuation and advanced-phase progression in tfr-eligible chronic myeloid leukemia: A multicenter retrospective cohort study

中文标题：TKI停药与TFR达标CML患者晚期进展的关联：一项多中心回顾性队列研究

报告人：Ting Lin

英文标题：Updated long-term efficacy and safety of tgrx-678, a novel STAMP inhibitor, in heavily pretreated TKI-resistant/intolerant CML patients from Phase 1 study tgrx -678-1001

中文标题：TGRX-678在重度预处理TKI耐药/不耐受CML中的长期疗效与安全性更新：I期研究TGRX-678-1001结果

报告人：Qian Jiang

英文标题：Cardio- and cerebrovascular adverse events during olverembatinib therapy in chronic myeloid leukemia: Incidences, outcomes, and risk factors

中文标题：奥雷巴替尼治疗CML期间心脑血管不良事件的发生率、结局及危险因素

报告人：Xiaoshuai Zhang

CLL/SLL

英文标题：Phase 2 study of birelentinib (DZD8586) monotherapy for treatment-Naïve and relapse/refractory patients with CLL/SLL (TAI-SHAN8)

中文标题：Birelentinib（DZD8586）单药治疗初治及R/R CLL/SLL患者的2期研究（TAI-SHAN8）

报告人：Wei Yang

英文标题：Multicenter phase II study (TAI-SHAN10): Combination of birelentinib and venetoclax in treatment-naïve CLL/SLL patients

中文标题：Birelentinib联合维奈克拉治疗初治CLL/SLL的多中心II期研究（TAI-SHAN10）

报告人：He Li

英文标题：MRD-guided sonrotoclax plus zanubrutinib in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma (SPRUCE-TN CLL/SLL)

中文标题：MRD指导下的索托克拉联合泽布替尼治疗初治CLL/SLL（SPRUCE-TN CLL/SLL）

报告人：Shuhua Yi

骨髓纤维化与真性红细胞增多症

英文标题：Updated efficacy and safety of flonoltinib maleate (FM) versus ruxolitinib (RUX) in patients with intermediate-2 or high-risk myelofibrosis: 48-week results from the phase 2 (FMF-02) study

中文标题：Flonoltinib maleate（FM）对比芦可替尼（RUX）治疗中危-2或高危MF患者的疗效与安全性更新：2期（FMF-02）研究48周结果

报告人：Lijuan Chen

英文标题：Phase Ib/II study of XPO1 inhibitor WJ01024 in combination with ruxolitinib in patients with myelofibrosis

中文标题：XPO1抑制剂WJ01024联合芦可替尼治疗MF患者的Ib/II期研究

报告人：Xuewen Song

英文标题：Safety and efficacy of the JAK/rock inhibitor rovadicitinib in combination with the bromodomain and extra-terminal inhibitor TQB3617 in patients with myelofibrosis: A open-label, multicenter, Phase Ib/II study

中文标题：JAK/ROCK抑制剂罗伐昔替尼联合溴结构域及超末端结构域（BET）抑制剂TQB3617治疗MF患者的安全性与疗效：一项开放标签、多中心Ib/II期研究

报告人：Youshan Zhao

英文标题：Efficacy and safety of OB756 versus best available therapy in hydroxyurea-resistant/intolerant polycythemia vera: An open-label, randomized, controlled, multicenter phase III clinical study

中文标题：OB756对比最佳可用疗法治疗羟基脲耐药/不耐受真性红细胞增多症的疗效与安全性：一项开放标签、随机对照、多中心III期临床研究

报告人：Jian Huang

ALL及其他淋巴增殖性疾病

英文标题：Nanobody-derived CD19/CD22 tandem CAR T-cell therapy for immune-refractory B-ALL after blinatumomab, inotuzumab, or single-target CAR T-cell therapy: The Phase II nanotrident-2 study

中文标题：纳米抗体来源的CD19/CD22串联CAR-T细胞治疗贝林妥欧单抗、奥加伊妥珠单抗或单靶点CAR-T治疗后免疫难治性B-ALL：II期NANOTRIDENT-2研究

报告人：Yihan Yang

英文标题：CD84 orchestrates metabolic reprogramming via HIF-1a stabilization and represents a safe, vulnerable therapeutic target in T-ALL

中文标题：CD84通过稳定HIF-1α驱动代谢重编程，是T-ALL中安全可成药的治疗靶点

报告人：Xuemei Wang

英文标题：Clinical activity and pharmacodynamic evidence of CD19 CAR T-cell therapy in relapsed/refractory idiopathic multicentric castleman disease: An expanded case series

中文标题：CD19 CAR-T细胞治疗复发/难治性特发性多中心Castleman病的临床活性与药效学证据：一项扩展病例系列

报告人：Yajing Zhang

B细胞淋巴瘤

英文标题：Pola-R2 in unfit/frail older patients with newly diagnosed DLBCL: Complete cohort analysis shows high CR rate and durable 24-month PFS

中文标题：Pola-R2治疗不适合/虚弱初治DLBCL老年患者：完整队列分析显示高CR率与持久24个月PFS率

报告人：Wei Wang

英文标题：Sequential glofitamab induction, anti-CD19 CAR T-cell therapy, and glofitamab maintenance for relapsed or refractory B-cell lymphoma: Results from a Phase Ib/II trial

中文标题：格菲妥单抗序贯诱导联合抗CD19 CAR-T及维持治疗复发/难治性B细胞淋巴瘤：Ib/II期研究结果

报告人：Yuting Yan

英文标题：Updated results from the phase 1 wavespan-001 study of MK-1045, a novel CD19 × CD3 T-cell engager, in participants with relapsed or refractory diffuse large B-cell lymphoma

中文标题：MK-1045治疗复发/难治性DLBCL：WAVESPAN-001 I期研究结果更新

报告人：Yuqin Song

英文标题：SP140 deficiency regulates the STMN3–XIAP splicing axis to drive resistance to BCL2 inhibitors in mantle cell lymphoma

中文标题：SP140缺失通过调控STMN3–XIAP剪接轴驱动套细胞淋巴瘤BCL-2抑制剂耐药

报告人：Xinyi Zhang

英文标题：Beyond cns-IPI: CSF-ctDNA as a superior risk predictor for cns relapse in newly-diagnosed diffuse large B-cell lymphoma

中文标题：超越CNS-IPI：CSF-ctDNA是初治DLBCL中枢复发的更优风险预测因子

报告人：Jinhua Liang

英文标题：FUT8-mediated core fucosylation of HSP90B1 stabilizes MYC and drives diffuse large B-cell lymphoma progression

中文标题：FUT8介导HSP90B1核心岩藻糖基化稳定MYC并驱动DLBCL进展

报告人：Han Zhang

英文标题：Yrdc-mediated tRNA t6a modification promotes MYC translational reprogramming to drive immune escape in diffuse large B-cell lymphoma

中文标题：YRDC介导tRNA t⁶A修饰促进MYC翻译重编程并驱动DLBCL免疫逃逸

报告人：Dujiang Fu

英文标题：Lipid metabolic reprogramming is associated with terminal exhaustion and impaired effector function of CD4+ T cells in HIV-associated DLBCL

中文标题：脂质代谢重编程与HIV相关DLBCL中CD4⁺ T细胞终末耗竭及效应功能受损相关

报告人：Xuejiao Shu

英文标题：Viral infections and reactivations following CAR-T cell therapy and their impact on survival outcomes in B-cell non-Hodgkin lymphoma: A real-world study of 641 patients

中文标题：B-NHL患者CAR-T治疗后病毒感染/再激活及其对生存结局的影响：641例患者的真实世界研究

报告人：Miaomiao Cao

T/NK细胞淋巴瘤

英文标题：Promising results from first-in-human phase 1 study of APG-5918, an embryonic ectoderm development (EED) inhibitor, for the treatment of patients with relapsed/refractory T-cell lymphoma (R/R TCL)

中文标题：APG-5918治疗R/R T细胞淋巴瘤：首次人体I期研究结果令人鼓舞

报告人：Qingqing Cai

英文标题：Igermetostat monotherapy in patients with relapsed /refractory peripheral T-cell lymphoma and follicular lymphoma: An open-label, first-in-human, phase 1/2 study

中文标题：Igermetostat单药治疗R/R PTCL和FL：开放标签首次人体I/II期研究

报告人：Bo Jiang

英文标题：A multi-center phase I study to assess the safety, immunogenicity, and preliminary antitumor activity of the EBV mRNA vaccine (WGc-043 injection) in patients with R/R lymphoma

中文标题：WGc-043（EBV mRNA疫苗）治疗R/R淋巴瘤的安全性、免疫原性及初步抗肿瘤活性：多中心I期研究

报告人：He Li

英文标题：A prospective phase II study of chidamide, tislelizumab, and pegaspargase (CTP) in combination with radiotherapy as first-line treatment in high-risk stages I and II of extranodal NK/T-cell lymphoma (ENKTL)

中文标题：CTP（西达本胺+替雷利珠单抗+培门冬酶）联合放疗一线治疗高危I/II期ENKTL：前瞻性II期研究

报告人：Yajun Li

英文标题：Sintilimab (anti-PD-1 antibody) combined with chidamide (an oral subtype-selective HDACi) followed by P-GemOx regimen in patients with treatment-naïve extranodal natural killer/T cell lymphoma (TN-ENKTL): A multicenter, open-label, single-arm, phase II study (SCENT-2 trial)

中文标题：信迪利单抗联合西达本胺序贯P-GemOx治疗初治ENKTL：SCENT-2多中心单臂II期研究

报告人：Gao Yan

英文标题：Interim results of the opti-seq study: A multicenter randomized phase II screening trial of three chemoradiotherapy strategies for early-stage extranodal NK/T-cell lymphoma

中文标题：OPTI-SEQ研究中期结果：早期结外NK/T细胞淋巴瘤三种放化疗策略的多中心随机II期筛选试验

报告人：Dahui Li

英文标题：A macrophage-associated CXCR3+ immune niche defines aggressive monomorphic epitheliotropic intestinal T-cell lymphoma

中文标题：巨噬细胞相关CXCR3⁺免疫微环境刻画侵袭性MEITL

报告人：Jinuo Wang

CAR-T 与细胞免疫治疗

英文标题：In vivo CD19 CAR T-cell generation in relapsed or refractory B-cell non-Hodgkin lymphoma: First-in-human Results

中文标题：体内生成CD19 CAR-T细胞治疗R/R B-NHL：首次人体研究结果

报告人：Huilei Miao

英文标题：Preliminary safety and efficacy of IASO208, a first-in-Human in vivo CD20-targeted third-generation CAR-T therapy, in relapsed/refractory B-cell non-Hodgkin lymphoma

中文标题：IASO208（体内靶向CD20第三代CAR-T）治疗R/R B-NHL的初步安全性与疗效：首次人体研究结果

报告人：Jia Xu

英文标题：A phase 1, open-label study of UB-VV400 +/- rapamycin in relapsed or refractory (R/R) B-cell malignancies

中文标题：UB-VV400 ± 雷帕霉素治疗R/R B细胞恶性肿瘤：I期开放标签研究

报告人：Xiaoyan Qu

英文标题：Safety and efficacy of the first CD19/BCMA dual-targeting in vivo CAR-T (QI-019A) for R/R multiple myeloma: A phase 1 study

中文标题：QI-019A（首个CD19/BCMA双靶点体内CAR-T）治疗RRMM的安全性与疗效：I期研究

报告人：Jia Xu

英文标题：First-in-human in vivo CD19 CAR-T-cell therapy with GT801 in refractory autoimmune hemolytic anemia: An interim analysis

中文标题：GT801体内CD19 CAR-T治疗难治性AIHA：首次人体研究中期分析

报告人：Pin Wang

英文标题：The novel CD19/ CD20 bispecific CAR/ truc-T therapy in relapsed/ refractory B-cell lymphoma

中文标题：新型CD19/CD20双特异性CAR/truc-T细胞疗法治疗R/R B细胞淋巴瘤

报告人：Chenguang Wang

英文标题：Integrated multi-omic and functional profiling identifies a 1q21.3–MLLT11 program associated with resistance to CD19 CAR T-cell therapy in large B-cell lymphoma

中文标题：整合多组学与功能分析揭示1q21.3–MLLT11程序驱动LBCL对CD19 CAR-T治疗耐药

报告人：Hesong Zou

英文标题：DGAT1-driven lipid metabolic reprogramming restrains CAR-T cell persistence and antitumor activity

中文标题：DGAT1驱动的脂质代谢重编程削弱CAR-T持久性与抗肿瘤活性

报告人：Yue Huang

英文标题：Enterococcus faecium-enriched gut enterotype and LPC(16:0)-associated myeloid inflammation are linked to grade 3 CRS after CD19 CAR-T therapy in R/R B-ALL: A longitudinal multi-omics study

中文标题：纵向多组学揭示肠球菌富集型肠道菌群与LPC(16:0)相关髓系炎症驱动R/R B-ALL患者CAR-T后3级CRS

报告人：Jinglei Yu

英文标题：Circadian disruption impairs CAR-T cell persistence through the BMAL1-TCF7-FOXO1 stemness axis

中文标题：昼夜节律紊乱经BMAL1-TCF7-FOXO1干性轴削弱CAR-T持久性

报告人：Wanying Zhang

英文标题：Molecular mechanisms of bystander cytotoxicity of bispecific T-cell engagers in hematological malignancies

中文标题：双特异性T细胞衔接器在血液肿瘤中介导旁观者细胞毒性的分子机制

报告人：Qi Ji

英文标题：Specific immunomodulation by OX40-targeted CAR-MSCs attenuates aGVHD

中文标题：OX40靶向CAR-MSCs经特异性免疫调节减轻aGVHD

报告人：Shuyan Chen

造血干细胞移植与移植物抗宿主病

英文标题：A prospective Phase 2 study of venetoclax plus decitabine–intensified conditioning followed by decitabine maintenance for TP53-mutated AML/MDS undergoing allo-HCT

中文标题：Ven+Dec强化预处理联合Dec维持用于TP53突变AML/MDS患者allo-HCT：一项前瞻性II期研究

报告人：Xiangjun Zeng

英文标题：The "=1 bridge" strategy versus extended chemotherapy approach in pre-transplant therapy in high-risk AML

中文标题：高危AML移植前治疗：“=1桥接”策略与延长化疗方案的比较

报告人：Xiaoyu Zhang

英文标题：Upfront transplantation versus pre-transplant cytoreductive therapy in myelodysplastic syndrome or secondary acute myeloid leukemia evolving from myelodysplastic syndrome: A prospective observational cohort study

中文标题：直接移植对比移植前细胞减灭治疗用于MDS或MDS继发AML：一项前瞻性观察性队列研究

报告人：Qifa Liu

英文标题：Comparable outcomes following haploidentical, MSD, and MUD HCT in adult AML patients with pre-transplant detectable MRD using PTCy-based GVHD prophylaxis: A study from the ALWP of the EBMT

中文标题：PTCy预防下Haplo、MSD与MUD移植在移植前MRD阳性成人AML中的结局比较：来自EBMT ALWP的研究

报告人：Yishan Ye

英文标题：Early consolidative HSCT promotes CD7+ T-cell recovery (TCR) and improves survival after CD7 CAR-T-cell therapy for R/R T-ALL: A 206-patient multicohort analysis

中文标题：早期巩固性HSCT促进CD7⁺ T细胞重建并改善R/R T-ALL患者CD7 CAR-T治疗后生存：206例患者的多队列分析

报告人：Min Zhang

英文标题：Addition of cyclophosphamide on day -1 significantly reduces graft rejection in TCRαβ-depleted haplo-HCT for thalassemia major

中文标题：第-1天加用环磷酰胺显著降低TCRαβ清除型单倍体移植治疗重型地中海贫血患者的移植物排斥

报告人：Jianyun Liao

英文标题：Higher HLA-DRB1 evolutionary divergence is associated with the HLA-loss phenotype among relapses after haploidentical hematopoietic cell transplantation

中文标题：更高的HLA-DRB1进化分歧度与单倍体造血干细胞移植后复发的HLA丢失表型相关

报告人：Ruowen Wei

英文标题：Skin-derived IL-17+CXCR6+T cells coordinate cross-organ immune regulation during reconstitution after allogeneic haematopoietic stem cell transplantation

中文标题：皮肤源性IL-17⁺CXCR6⁺ T细胞协调异基因造血干细胞移植后重建期的跨器官免疫调控

报告人：Rui Ji

英文标题：Durable responses and prolonged failure-free survival with highly selective oral CSF-1R inhibitor pimicotinib in relapsed or refractory chronic graft-versus-host disease: Mature follow-up from a multicenter Phase 2 study

中文标题：高选择性口服CSF-1R抑制剂Pimicotinib治疗R/R cGVHD：持久缓解与延长的FFS——多中心II期研究成熟随访

报告人：Xiao-Dong Mo

英文标题：Safety and efficacy of iPSC-derived mesenchymal stromal cells (NCR102) in gastrointestinal-involved steroid-refractory aGVHD after failure of second-line therapy: A phase I/II trial

中文标题：iPSC来源的间充质基质细胞（NCR102）治疗二线失败后胃肠道受累SR-aGVHD的安全性与有效性：I/II期研究

报告人：Yi He

英文标题：First-in-human trial of off-the-shelf iNKT cell therapy GT729 in patients with refractory or relapsed cgvhd after allogeneic hematopoietic cell transplantation

中文标题：现货型iNKT细胞疗法GT729治疗allo-HCT后R/R cGVHD的首次人体试验

报告人：Xiaoyu Zhang

英文标题：Hope for parenthood: Pregnancy outcomes after ATG-based haploidentical hematopoietic stem cell transplantation using nationally representative data

中文标题：ATG方案单倍体移植后妊娠结局：一项基于全国代表性数据的分析

报告人：Qiu-Sha Huang

ITP与出凝血疾病

英文标题：Hetrombopag plus high-dose dexamethasone versus high-dose dexamethasone alone as first-line therapy for newly diagnosed primary immune thrombocytopenia: A multicenter, open-label, randomized phase II trial

中文标题：海曲泊帕联合大剂量地塞米松对比大剂量地塞米松单药一线治疗新诊断原发ITP：一项多中心、开放标签、随机II期试验

报告人：Yu Hou

英文标题：Orelabrutinib, an oral BTK inhibitor, for previously treated chronic primary immune thrombocytopenia in Chinese adults: A phase 3, placebo-controlled, multicenter trial

中文标题：口服BTK抑制剂奥布替尼治疗中国成人既往经治的慢性原发ITP：一项3期、安慰剂对照、多中心试验

报告人：Yu Hou

英文标题：Switch from eltrombopag to avatrombopag in pediatric and adolescent immune thrombocytopenia: A single-arm, open-label clinical study

中文标题：儿童及青少年ITP中由艾曲泊帕转换为阿伐曲泊帕：一项单臂、开放标签临床研究

报告人：Sun Ting

英文标题：Targeting the ERa/HIF-1a metabolic checkpoint: Tofacitinib suppresses macrophage glycolysis and phagocytosis in immune thrombocytopenia during pregnancy

中文标题：靶向ERα/HIF-1α代谢检查点：托法替布抑制妊娠期ITP中巨噬细胞的糖酵解与吞噬作用

报告人：Jie Chen

英文标题：Pre-treatment B-cell activating factor (BAFF) levels are associated with rituximab non-response and correlate with distinct immune phenotypes in pediatric immune thrombocytopenia: A prospective cohort study

中文标题：治疗前B细胞活化因子（BAFF）水平与儿童ITP利妥昔单抗无应答相关并对应不同免疫表型：一项前瞻性队列研究

报告人：Jingyao Ma

英文标题：First-in-human clinical trial of an off-the-shelf allogeneic megakaryocyte product for refractory thrombocytopenia after allogeneic hematopoietic stem cell transplantation

中文标题：通用型异基因巨核细胞产品治疗allo-HSCT后难治性血小板减少症的首次人体试验

报告人：Xiaoyu Zhu

英文标题：Efficacy and safety of romiplostim N01 versus recombinant human interleukin-11 in the treatment of cancer therapy-induced thrombocytopenia: A prospective, randomized, controlled trial

中文标题：罗米司亭N01（Romiplostim N01）对比重组人白介素-11治疗肿瘤治疗相关血小板减少的疗效与安全性：一项前瞻性、随机对照试验

报告人：Xiaofeng Chen

英文标题：Efficacy and safety of low-dose decitabine combined with thrombopoietin receptor agonists in refractory severe chemotherapy-induced thrombocytopenia: A retrospective analysis with prognostic factor identification

中文标题：低剂量地西他滨联合血小板生成素受体激动剂治疗难治性重度化疗相关血小板减少的疗效与安全性：一项含预后因素识别的回顾性分析

报告人：Bingjie Ding

英文标题：Preliminary efficacy and safety of SR604 for bleeding prophylaxis in von Willebrand disease: Results from an ongoing phase II study

中文标题：SR604用于血管性血友病出血预防的初步疗效与安全性：一项正在进行中的II期研究结果

报告人：Yue Han

PNH与骨髓衰竭

英文标题：FXS6837 (STL303/XH-S003), an oral complement factor B inhibitor, showed clinically meaningful anemia improvement in PNH patients: First results from a randomized Phase 2 study

中文标题：口服补体B因子抑制剂FXS6837（STL303/XH-S003）在PNH患者中显示出具有临床意义的贫血改善：一项随机2期研究的首次结果

报告人：Hui Liu

英文标题：Once-daily oral NTQ5082 in complement inhibitor-naïve paroxysmal nocturnal hemoglobinuria: Results from a phase 3 study

中文标题：每日一次口服NTQ5082治疗补体抑制剂初治的PNH：一项3期研究结果

报告人：Fengkui Zhang

血红蛋白病与红细胞疾病

英文标题：Real-world efficacy and safety of luspatercept in Chinese adults with transfusion-dependent beta-thalassemia

中文标题：罗特西普在中国成人输血依赖型β-地中海贫血中的真实世界疗效与安全性

报告人：Cailan Wen

HLH与组织细胞疾病

英文标题：Golidocitinib monotherapy for adult hemophagocytic lymphohistiocytosis: Interim efficacy and safety results from a prospective single-arm trial (JACKPOT11)

中文标题：戈利昔替尼单药治疗成人HLH：一项前瞻性单臂试验（JACKPOT11）的中期疗效与安全性结果

报告人：Jingshi Wang

英文标题：Dynamic plasma EBV-DNA at 6 and 12 months, but not baseline, independently predicts survival in relapsed/refractory adult EBV-HLH treated with PD-1 inhibitors

中文标题：PD-1抑制剂治疗R/R成人EBV-HLH：第6、12个月动态EBV-DNA（而非基线）独立预测生存

报告人：Yang Dai

英文标题：Decitabine restrains hyperinflammation through P21-mediated cell cycle arrest in hemophagocytic lymphohistiocytosis

中文标题：地西他滨通过P21介导的细胞周期阻滞抑制HLH过度炎症

报告人：Xinyue Deng

英文标题：A multicenter, open-label phase 1b dose-exploration and expansion study of oric-1940, a RIPK1 inhibitor, combined with Etoposide–Dexamethasone in refractory adult HLH

中文标题：RIPK1抑制剂ORIC-1940联合依托泊苷-地塞米松治疗难治性成人HLH的多中心、开放标签1b期剂量探索与扩展研究

报告人：Luocheng Zhang

英文标题：XPO1 inhibition remodels the inflammatory and metabolic microenvironment in BRAFV600E langerhans cell histiocytosis

中文标题：XPO1抑制重塑BRAF V600E朗格汉斯细胞组织细胞增生症的炎症与代谢微环境

报告人：Zheng-Zheng Liu

基础、转化与新技术

英文标题：Identification of mast cells as a conserved niche component for hematopoietic stem cell development

中文标题：肥大细胞被鉴定为造血干细胞发育的保守微环境组分

报告人：Zining Yang

英文标题：Structure-guided cyclic peptide decoy design for interception of anti-AAV8 neutralizing antibodies

中文标题：基于结构引导的环肽诱饵设计用于拦截抗AAV8中和抗体

报告人：Bingqi Xu

英文标题：A pretreatment transcriptomic-clinical signature for predicting high-dose methotrexate-associated nephrotoxicity in childhood acute lymphoblastic leukemia

中文标题：治疗前转录组-临床联合特征预测儿童ALL大剂量甲氨蝶呤相关肾毒性

报告人：Youzhi Cui

如有遗漏，欢迎留言区补充~